INmune Bio Inc. Common stock (INMB) — Analysis Summary
INmune Bio Inc. Common stock (INMB) has a market cap of $37.49M with year-over-year revenue growth of +257.1%. Net margin stands at -91866.0%. The stock trades at a P/E ratio of -0.9.
Key Takeaways
- Revenue changed +257.1% year-over-year
- Net margin of -91866.0%
- P/E ratio of -0.9
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, INMB posted revenue growth of +257.1% and trades at a P/E of -0.9.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.